Ultragenyx Pharmaceutical Inc.
DE ˙ DB ˙ US90400D1081
19,12 € ↑0,58 (3,13%)
2026-06-04
DEL PRIS
SecurityDE:UP0 / Ultragenyx Pharmaceutical Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership535,566 shares
Latest Disclosed Value $ 11,220,107
Northern Trust Corp reports 1.69% increase in ownership of UP0 / Ultragenyx Pharmaceutical Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 535,566 shares of Ultragenyx Pharmaceutical Inc. (DE:UP0) valued at $9,051,065 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 526,686 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of 1.69% during the quarter. The current value of the position is $10,237,344 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 535,566 8,880 1.69 11,220 -7.37 0.0015
2026-02-17 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 526,686 27,454 5.50 12,114 -19.33 0.0015
2025-11-14 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 499,232 5,762 1.17 15,017 -16.31 0.0019
2025-08-13 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 493,470 -74,919 -13.18 17,943 -12.82 0.0025
2025-05-13 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 568,389 39,424 7.45 20,581 -7.51 0.0031
2025-02-14 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 528,965 55,641 11.76 22,254 -15.37 0.0032
2024-11-13 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 473,324 91,443 23.95 26,293 67.52 0.0043
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 381,881 14,258 3.88 15,695 -8.56 0.0026
2024-05-14 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 367,623 -7,038 -1.88 17,164 -4.20 0.0030
2024-02-13 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 374,661 52,090 16.15 17,916 55.80 0.0032
2023-11-13 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 322,571 10,208 3.27 11,500 -20.20 0.0022
2023-08-11 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 312,363 7,653 2.51 14,409 17.93 0.0028
2023-05-15 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 304,710 6,897 2.32 12,219 -11.44 0.0024
2023-02-13 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 297,813 -39,183 -11.63 13,798 -1.13 0.0029
2022-11-14 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 336,996 1,503 0.45 13,955 -30.28 0.0032
2022-08-12 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 335,493 -2,203 -0.65 20,015 -18.38 0.0043
2022-05-13 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 337,696 -1,853 -0.55 24,523 -14.11 0.0043
2022-02-08 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 339,549 -3,264 -0.95 28,553 -7.65 0.0047
2021-11-15 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 342,813 -1,268 -0.37 30,919 -5.76 0.0055
2021-08-13 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 344,081 -387,487 -52.97 32,808 -60.61 0.0058
2021-05-12 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 731,568 -44,223 -5.70 83,296 -22.44 0.0155
2021-02-11 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 775,791 33,536 4.52 107,393 76.04 0.0209
2020-11-16 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 742,255 -36,194 -4.65 61,006 0.19 0.0134
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 778,449 57,346 7.95 60,890 90.05 0.0144
2020-05-14 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 721,103 10,650 1.50 32,039 5.59 0.0092
2020-02-14 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 710,453 -13,724 -1.90 30,343 -2.06 0.0068
2019-11-13 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 724,177 33,067 4.78 30,981 -29.41 0.0074
2019-08-13 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 691,110 32,812 4.98 43,886 -3.89 0.0104
2019-05-13 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 658,298 77,718 13.39 45,660 80.88 0.0113
2019-02-12 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 580,580 11,258 1.98 25,243 -41.92 0.0071
2018-11-14 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 569,322 15,230 2.75 43,463 2.04 0.0106
2018-09-18 2018-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 554,092 34,942 6.73 42,594 60.91 0.0108
2018-08-14 2018-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 557,273 38,123 42,838
2018-05-09 2018-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 519,150 58,507 12.70 26,471 23.90 0.0069
2018-02-14 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 460,643 -11,376 -2.41 21,364 -15.02 0.0054
2017-11-13 2017-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 472,019 -5,382 -1.13 25,140 -15.21 0.0066
2017-08-11 2017-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 477,401 19,138 4.18 29,651 -4.54 0.0083
2017-05-12 2017-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 458,263 29,537 6.89 31,060 3.04 0.0090
2017-02-13 2016-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 428,726 3,952 0.93 30,144 0.03 0.0092
2016-11-09 2016-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 424,774 -920 -0.22 30,134 44.73 0.0094
2016-08-12 2016-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 425,694 -16,054 -3.63 20,821 -27.12 0.0068
2016-08-19 2016-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 441,748 12,775 2.98 28,570 -40.63 0.0095
2016-05-13 2016-03-31 13F Ultragenyx Pharmaceutic COMM 90400D108 441,748 27,968
2016-02-12 2015-12-31 13F Ultragenyx Pharmaceutic COMM 90400D108 428,973 8,441 2.01 48,122 18.81 0.0160
2015-11-12 2015-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 420,532 420,532 0.00 40,503 0.0135
2015-08-13 2015-06-30 13F Ultragenyx Pharmaceutic COMM 90400D108 0 -111,688 -100.00 0 -100.00
2015-05-14 2015-03-31 13F Ultragenyx Pharmaceutic COMM 90400D108 111,688 7,596 7.30 6,935 51.82 0.0021
2015-02-12 2014-12-31 13F Ultragenyx Pharmaceutic COM 90400D108 104,092 -465 -0.44 4,568 -22.80 0.0014
2014-11-13 2014-09-30 13F Ultragenyx Pharmaceutic COMM 90400D108 104,557 17,746 20.44 5,917 51.83 0.0019
2014-08-14 2014-06-30 13F ULTRAGENYX PHARMACEUTICAL IN com 90400D108 86,811 57,872 199.98 3,897 175.60 0.0012
2014-05-14 2014-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COMM 90400D108 28,939 28,939 1,414 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.